



BRITISH COLUMBIA
CENTRE *for* EXCELLENCE
in HIV/AIDS

B.C. HIV/AIDS Drug Treatment Program

Monthly Report

April 2022





© 2022 BC Centre for Excellence in HIV/AIDS

DISCLAIMER: This document is published by the British Columbia Centre for Excellence in HIV/AIDS (BC-CfE) as an overview of the activities of the BC-CfE's Drug Treatment Program. All information is generated from a live database maintained by the BC-CfE that houses data for clinical and virological outcome studies of patients receiving antiretroviral therapy.

This database is updated on a regular basis. Figures and tables provided in this Monthly Report represent the best estimates available at the time this document was generated.

Please be advised that information provided in this document is provided in good faith and is derived from sources believed to be accurate and up-to-date at the report's date of publication. The BC Centre for Excellence in HIV/AIDS nevertheless reserves the right to update this information at any time.

Information provided here at this time, is being provided freely, and no kind of agreement or contract is created between you and the authors. The authors cannot be responsible for any violations should you reproduce or republish the information contained herein.

Please note that the figures and graphs in this document are best viewed in colour.

BC Centre for Excellence in HIV/AIDS Drug Treatment Program

St. Paul's Hospital
687 - 1081 Burrard Street
Vancouver, BC
V6Z 1Y6

Tel: 604.806.8515
Fax: 604.806.9044

Physician Drug Hotline: 1.800.665.7677
St. Paul's Hospital Pharmacy Hotline: 1.888.511.6222
Website: www.bccfe.ca
Email: info@bccfe.ca

Funding for the BC Centre for Excellence in HIV/AIDS is provided through Pharmacare and the Provincial Health Services Authority (PHSA)





EXECUTIVE SUMMARY

A key component of the BC Centre for Excellence in HIV/AIDS' (BC-CfE) mandate is to monitor the impact of HIV/AIDS in British Columbia. The BC-CfE provides essential information to local health authorities, treating physicians, and the community at large on an ongoing basis. The HIV/AIDS Drug Treatment Program (DTP) Update is one example of the BC-CfE's commitment to HIV-infected persons throughout the Province of British Columbia.

The DTP distributes anti-HIV drugs at no cost to eligible British Columbians. The DTP Update provides an important overview of available anti-HIV drugs, common drug combinations and distribution of active DTP participants throughout the province.

DTP participants are typically followed at three-monthly intervals at which time routine blood sampling is performed. Information from all recipients is entered into a database, providing data for clinical and virological outcome studies of patients receiving antiretroviral therapy. These studies form the basis of ongoing revisions to the BC-CfE's treatment guidelines.





TABLE OF CONTENTS

1. List of Figures

- 1.1 Distribution of males and females on antiretroviral therapy in British Columbia by Health Authority
- 1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Category
- 1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Category
- 1.4 BC-CfE Enrolment: Net Number of New Antiretroviral Participants
- 1.5 BC-CfE Enrolment: New Antiretroviral Participants
- 1.6 Percent Distribution of Active Participants by CD4 Count
- 1.7 Percent Distribution of Inactive Participants by CD4 Count
- 1.8 Active and Inactive Participants
- 1.9 Percent Distribution of Participants on ARV Therapy by Number of Drugs
- 1.10 Distribution of Participants on Nucleoside/Nucleotide Analogues by Ingredient
- 1.11 Distribution of Participants on Nucleoside/Nucleotide Analogues at the time of first start of ARV Therapy by Ingredient
- 1.12 Distribution of Participants on Protease Inhibitor by Ingredient
- 1.13 Distribution of Participants on Protease Inhibitor at the time of first start of ARV Therapy by Ingredient
- 1.14 Distribution of Participants on Non-Nucleosides by Ingredient
- 1.15 Distribution of Participants on Non-Nucleosides at the time of first start of ARV Therapy by Ingredient
- 1.16 Distribution of Participants on Entry/Integrase Inhibitors by Ingredient
- 1.17 Distribution of Participants on Entry/Integrase Inhibitors at the time of first start of ARV Therapy by Ingredient
- 1.18 Baseline CD4 for Antiretroviral First Starts
- 1.19 DTP Participants with PVL Measurement within previous five years, and never on ART
- 1.20 Cumulative Resistance Testing Results by Resistance Category
- 1.21 Percent of Participants ever on ARV - Resistance Testing Results by Resistance Category

2. List of Tables

- 2.1 Duration of ARV treatment in the Province of BC, 1987-2022 (for HIV+ persons currently on treatment)
- 2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program
- 2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program
- 2.4 BC-CfE Enrolment
- 2.5 Percent Distribution of Participants on ARV Therapy by Number of Drugs
- 2.6 Number of Participants on Nucleoside/Nucleotide Analogues by Ingredient
- 2.7 Number of Participants on Protease Inhibitor by Ingredient
- 2.8 Number of Participants on Non-Nucleosides by Ingredient
- 2.9 Number of Participants on Entry/Integrase Inhibitors by Ingredient
- 2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Category
- 2.11 Baseline CD4 for Antiretroviral First Starts
- 2.12 DTP Participants with PVL Measurement within previous five years, and never on ART





Table of Contents, cont'd...

3. Health Authority Maps

- 3.1 Distribution of HIV/AIDS Drug Treatment Program Active Participants
- 3.2 Interior Health Authority & Kelowna
- 3.3 Fraser Health Authority & Surrey
- 3.4 Vancouver Coastal Health Authority & Vancouver
- 3.5 Vancouver Island Health Authority & Victoria
- 3.6 Northern Health Authority & Prince George

4. Health Authority Tables

INTERIOR HEALTH

- 4.1 Distribution of Participants in BC-CfE Registries by Age and Sex at birth
- 4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.3 Distribution of ARV Prescribers in BC-CfE Registries

FRASER HEALTH

- 4.4 Distribution of Participants in BC-CfE Registries by Age and Sex at birth
- 4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.6 Distribution of ARV Prescribers in BC-CfE Registries

VANCOUVER COASTAL

- 4.7 Distribution of Participants in BC-CfE Registries by Age and Sex at birth
- 4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.9 Distribution of ARV Prescribers in BC-CfE Registries

VANCOUVER ISLAND

- 4.10 Distribution of Participants in BC-CfE Registries by Age and Sex at birth
- 4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.12 Distribution of ARV Prescribers in BC-CfE Registries

NORTHERN HEALTH

- 4.13 Distribution of Participants in BC-CfE Registries by Age and Sex at birth
- 4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.15 Distribution of ARV Prescribers in BC-CfE Registries

ABORIGINAL

- 4.16 Distribution of Indigenous Participants in BC-CfE Registries by Health Service Delivery Area and Sex at birth

5. Appendix

- 5.1 Drug Names and Definitions






1.1 Distribution of males and females on antiretroviral therapy in British Columbia by Health Authority

April 2022

N = 7436



Health Authority	Male	Female	All
FRASER	1466	448	1914
INTERIOR	429	111	540
NORTHERN	143	79	222
VANCOUVER COASTAL	3313	435	3748
VANCOUVER ISLAND	805	164	969
	6156	1237	7393
		Unknown/not stated:	43
		Total:	7436

Definitions:

On antiretroviral therapy defined as being on treatment in the current month


Unknown/not stated defined as being on treatment in the current month, and city of residence unknown

Male & Female refer to Sex at birth





1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Category (April 2017 - April 2022)




Notes:

Regimen categories may contain a small number of participants with undetermined regimen, due to medication change(s) within the month





1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Category (April 2017 - April 2022)




Notes:

Regimen categories may contain a small number of participants with undetermined regimen, due to medication change(s) within the month






1.4 BC-CfE Enrolment: Net Number of New Antiretroviral Participants (April 2017 - April 2022)






1.5 BC-CfE Enrolment: New Antiretroviral Participants (April 2017 - April 2022)






1.6 Percent Distribution of Active Participants by CD4 Count
(April 2017 - April 2022)






1.7 Percent Distribution of Inactive Participants by CD4 Count (April 2017 - April 2022)






1.8 Active and Inactive Participants (April 2017 - April 2022)






1.9 Percent Distribution of Participants on ARV Therapy by Number of Drugs (April 2017 - April 2022)






1.10 Distribution of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT (April 2017 - April 2022)






1.11 Distribution of Participants on Nucleoside/Nucleotide Analogues at the time of first start of ARV Therapy by INGREDIENT

(April 2017 - April 2022)






1.12 Distribution of Participants on Protease Inhibitor by INGREDIENT (April 2017 - April 2022)






1.13 Distribution of Participants on Protease Inhibitor at the time of first start of ARV Therapy by INGREDIENT

(April 2017 - April 2022)






1.14 Distribution of Participants on Non-Nucleosides by INGREDIENT (April 2017 - April 2022)






1.15 Distribution of Participants on Non-Nucleosides at the time of first start of ARV Therapy by INGREDIENT

(April 2017 - April 2022)






1.16 Distribution of Participants on Entry/Integrase Inhibitors by INGREDIENT (April 2017 - April 2022)






1.17 Distribution of Participants on Entry/Integrase Inhibitors at the time of first ARV Therapy by INGREDIENT

(April 2017 - April 2022)






1.18 Baseline CD4 for Antiretroviral First Starts
(April 2017 - April 2022)






1.19 DTP Participants with PVL Measurement within previous five years, and never on ART (April 2017 - April 2022)






1.20 Cumulative Resistance Testing Results by Resistance Category (April 2017 - April 2022)





1.21 Percent of Participants ever on ARV - Resistance Testing Results by Resistance Category (April 2017 - April 2022)





**2.1 Duration of ARV treatment in the Province of BC, 1987-2022
(for HIV+ persons currently on treatment)**

Start Year	Duration (years) Median	Male	Female	All	Current CD4 (n)	Median	Current PVL (n)	Median	Current ARV Median
1987	30	4	0	4	1	950	4	<40	4
1988	31	5	0	5	3	400	5	<40	3
1989	29	50	1	51	27	530	46	<40	3
1990	28	53	1	54	27	580	50	<40	3
1991	28	37	3	40	17	620	37	<40	3
1992	28	56	5	61	26	530	57	<40	3
1993	27	123	14	137	82	530	131	<40	3
1994	25	73	12	85	58	540	76	<40	3
1995	25	121	18	139	84	535	127	<40	3
1996	23	312	45	357	218	550	334	<40	3
1997	21	258	31	289	174	605	259	<40	3
1998	21	186	41	227	135	540	196	<40	3
1999	21	155	37	192	121	580	171	<40	3
2000	21	115	27	142	88	615	123	<40	3
2001	20	110	25	135	81	570	119	<40	3
2002	19	119	25	144	99	540	130	<40	3
2003	19	134	27	161	100	630	150	<40	3
2004	17	149	36	185	120	610	165	<40	3
2005	17	173	42	215	142	625	197	<40	3
2006	16	166	38	204	133	590	185	<40	3
2007	15	224	45	269	175	630	235	<40	3
2008	14	275	61	336	227	641	304	<40	3
2009	13	298	66	364	240	637	329	<40	3
2010	12	257	66	323	206	700	286	<40	3
2011	11	316	67	383	247	710	339	<40	3
2012	10	264	65	329	202	690	295	<40	3
2013	9	249	66	315	209	700	281	<40	3
2014	8	265	48	313	188	707	273	<40	3
2015	7	267	41	308	200	705	270	<40	3
2016	6	253	52	305	183	654	260	<40	3
2017	5	213	29	242	166	666	222	<40	3
2018	4	188	55	243	163	750	219	<40	3

Definitions:

On treatment defined as being on ARV therapy in the specified month and not reported deceased

Duration defined as cumulative years on ARV therapy, excluding periods of treatment interruption

Current CD4 and PVL tests defined as tests done in the last 6 months (most recent)

Current ARV defined as number of ARV drugs in the current regimen





**2.1 Duration of ARV treatment in the Province of BC, 1987-2022
(for HIV+ persons currently on treatment)**

Start Year	Duration (years) Median	Male	Female	All	Current CD4 (n)	Current CD4 Median	Current PVL (n)	Current PVL Median	Current ARV Median
2019	3	232	39	271	189	680	238	<40	3
2020	2	188	51	239	170	700	211	<40	3
2021	1	215	43	258	178	572	233	<40	3
2022	0	73	16	89	74	620	84	<40	3
Total:		6176	1238	7414					

Definitions:

On treatment defined as being on ARV therapy in the specified month and not reported deceased

Duration defined as cumulative years on ARV therapy, excluding periods of treatment interruption

Current CD4 and PVL tests defined as tests done in the last 6 months (most recent)

Current ARV defined as number of ARV drugs in the current regimen



2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program

MON-YYYY	# of patients	Median # of therapy days	# of patients with PVL test	Median PVL	# of patients with CD4 test	Median CD4
JAN-2021	7384	746	1942	<40	1393	630
FEB-2021	7377	748	1787	<40	1276	630
MAR-2021	7432	743	2015	<40	1427	620
APR-2021	7417	746	1828	<40	1324	636
MAY-2021	7452	742	1868	<40	1305	630
JUN-2021	7456	738	1880	<40	1354	610
JUL-2021	7460	744	1820	<40	1346	640
AUG-2021	7465	741	1981	<40	1354	630
SEP-2021	7432	750	1763	<40	1244	630
OCT-2021	7432	755	1855	<40	1287	630
NOV-2021	7446	750	2021	<40	1371	630
DEC-2021	7462	757	1543	<40	1034	630
JAN-2022	7466	756	1879	<40	1299	650
FEB-2022	7391	774	1803	<40	1241	620
MAR-2022	7466	766	1905	<40	1191	630
APR-2022	7436	775	1756	<40	1075	630

Definitions:

Active patient defined as being on ARV treatment in the specified month

Therapy days defined as number of consecutive days on ARV treatment (most recent uninterrupted period)

PVL and CD4 tests defined as tests done in the specified month

2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program

MON-YYYY	# of patients	Median # days of off therapy	# of patients with PVL test	Median PVL	# of patients with CD4 test	Median CD4
JAN-2021	774	196	73	<40	57	510
FEB-2021	786	196	69	<40	56	510
MAR-2021	770	247	89	<40	71	630
APR-2021	803	255	73	<40	58	615
MAY-2021	781	270	73	<40	65	530
JUN-2021	779	262	65	57	49	540
JUL-2021	780	274	52	102	37	530
AUG-2021	786	264	53	<40	41	630
SEP-2021	829	229	64	<40	41	610
OCT-2021	832	240	79	<40	60	540
NOV-2021	816	264	78	<40	60	446
DEC-2021	796	248	48	<40	31	360
JAN-2022	787	273	54	<40	41	610
FEB-2022	854	236	73	<40	52	620
MAR-2022	796	286	93	<40	69	470
APR-2022	830	290	69	<40	49	550

Definitions:

Inactive patient defined as not deceased, not being on ARV treatment in the specified month (but previously treated with ARVs), and had contact with program in past 5 years

Days off therapy defined as number of days elapsed since last ARV treatment

PVL and CD4 tests defined as tests done in the specified month



2.4 BC-CfE Enrolment

MON-YYYY	Currently on ARV Therapy	Currently off ARV Therapy	Deceased	First Starts	Experienced Starts	New Inactive	Net Change	Cumulative Patients
JAN-2021	7358	774	14	9	205	160	36	14210
FEB-2021	7351	786	15	13	186	189	-7	14234
MAR-2021	7404	770	15	24	203	156	53	14271
APR-2021	7390	803	13	9	165	172	-14	14296
MAY-2021	7418	781	14	14	177	143	28	14325
JUN-2021	7435	779	7	15	186	174	17	14351
JUL-2021	7438	780	9	12	170	166	3	14371
AUG-2021	7436	786	16	12	174	167	-2	14393
SEP-2021	7400	829	14	9	174	199	-36	14423
OCT-2021	7393	832	17	6	186	174	-7	14446
NOV-2021	7420	816	11	15	199	175	27	14472
DEC-2021	7433	796	22	6	204	174	13	14490
JAN-2022	7436	787	19	7	162	144	3	14505
FEB-2022	7380	854	8	9	151	208	-56	14530
MAR-2022	7444	796	16	9	234	159	64	14560
APR-2022	7414	830	10	1	159	179	-30	14580

Definitions:

Currently on ARV Therapy defined as being on ARV treatment in the specified month, and not deceased/moved out of BC

Currently off ARV Therapy defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARVs in the past

Deceased defined as deceased in the specified month, and being on ARV treatment in the previous month

First Starts defined as starting ARV treatment in the specified month for the first time (ARV naive)

Experienced Starts defined as starting ARV treatment in the specified month, but previously being treated with ARVs

New Inactive defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARV treatment in the previous month, and had contact with the program in the past 5 years

Net Change is defined as difference between ARV starts (First and Experienced) and ARV stops (Deceased/Moved out of BC and New Inactive)





2.5 Percent Distribution of Participants on ARV Therapy by Number of Drugs

MON-YYYY	Less than 3 Drugs	3 Drugs	4 Drugs	5 or more Drugs	All ARV	Less than 3 Drugs%	3 Drugs%	4 Drugs%	5 or more Drugs%	Total%
JAN-2021	205	6681	452	46	7384	2.78%	90.48%	6.12%	0.62%	100.00%
FEB-2021	226	6652	448	51	7377	3.06%	90.17%	6.07%	0.69%	100.00%
MAR-2021	249	6669	463	51	7432	3.35%	89.73%	6.23%	0.69%	100.00%
APR-2021	275	6644	454	44	7417	3.71%	89.58%	6.12%	0.59%	100.00%
MAY-2021	299	6640	465	48	7452	4.01%	89.10%	6.24%	0.64%	100.00%
JUN-2021	326	6613	471	46	7456	4.37%	88.69%	6.32%	0.62%	100.00%
JUL-2021	354	6590	470	46	7460	4.75%	88.34%	6.30%	0.62%	100.00%
AUG-2021	381	6571	471	42	7465	5.10%	88.02%	6.31%	0.56%	100.00%
SEP-2021	398	6525	462	47	7432	5.36%	87.80%	6.22%	0.63%	100.00%
OCT-2021	409	6517	460	46	7432	5.50%	87.69%	6.19%	0.62%	100.00%
NOV-2021	438	6508	457	43	7446	5.88%	87.40%	6.14%	0.58%	100.00%
DEC-2021	468	6492	457	45	7462	6.27%	87.00%	6.12%	0.60%	100.00%
JAN-2022	499	6468	455	44	7466	6.68%	86.63%	6.09%	0.59%	100.00%
FEB-2022	525	6375	446	45	7391	7.10%	86.25%	6.03%	0.61%	100.00%
MAR-2022	550	6415	456	45	7466	7.37%	85.92%	6.11%	0.60%	100.00%
APR-2022	567	6373	450	46	7436	7.63%	85.70%	6.05%	0.62%	100.00%

Definitions:

Number of Drugs is calculated as number of individual drugs in ARV Therapy (excluding low dose ritonavir used for boosting a protease inhibitor)





2.6 Number of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT

	lamivudine		abacavir		zidovudine		tenofovir <TAF>		tenofovir <TDF>		emtricitabine	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2021	2 10%	3153 44%	1 5%	2880 40%	0 0%	28 0%	12 60%	2220 31%	6 30%	1962 27%	18 90%	4045 56%
FEB-2021	2 8%	3135 43%	2 8%	2843 39%	0 0%	27 0%	16 67%	2298 32%	6 25%	1899 26%	22 92%	4061 56%
MAR-2021	8 22%	3140 43%	7 19%	2832 39%	0 0%	24 0%	23 62%	2368 33%	6 16%	1858 26%	29 78%	4111 57%
APR-2021	2 8%	3137 43%	2 8%	2802 39%	0 0%	25 0%	17 68%	2422 33%	6 24%	1791 25%	23 92%	4104 57%
MAY-2021	7 24%	3150 43%	3 10%	2784 38%	0 0%	22 0%	15 52%	2497 34%	10 34%	1759 24%	22 76%	4131 57%
JUN-2021	4 15%	3137 43%	3 12%	2741 38%	0 0%	23 0%	17 65%	2574 35%	5 19%	1698 23%	22 85%	4153 57%
JUL-2021	3 15%	3126 43%	2 10%	2707 37%	0 0%	23 0%	13 65%	2626 36%	4 20%	1655 23%	17 85%	4166 57%
AUG-2021	1 5%	3109 43%	1 5%	2667 37%	0 0%	23 0%	16 73%	2660 36%	5 23%	1631 22%	21 95%	4182 57%
SEP-2021	4 13%	3078 42%	2 7%	2614 36%	1 3%	22 0%	21 70%	2707 37%	5 17%	1587 22%	26 87%	4178 57%
OCT-2021	5 22%	3082 42%	5 22%	2591 36%	0 0%	20 0%	13 57%	2755 38%	5 22%	1563 21%	18 78%	4196 58%
NOV-2021	3 12%	3071 42%	2 8%	2552 35%	0 0%	19 0%	18 72%	2812 39%	4 16%	1534 21%	22 88%	4216 58%
DEC-2021	3 18%	3067 42%	1 6%	2514 34%	0 0%	19 0%	10 59%	2861 39%	5 29%	1503 21%	14 82%	4237 58%
JAN-2022	3 20%	3065 42%	3 20%	2481 34%	0 0%	19 0%	12 80%	2922 40%	0 0%	1473 20%	12 80%	4262 58%
FEB-2022	6 24%	3020 42%	3 12%	2411 33%	2 8%	19 0%	15 60%	2941 41%	4 16%	1397 19%	19 76%	4229 58%
MAR-2022	3 10%	3035 41%	2 7%	2406 33%	0 0%	19 0%	25 83%	3033 41%	2 7%	1353 18%	27 90%	4279 58%
APR-2022	4 20%	3026 42%	3 15%	2371 33%	0 0%	19 0%	14 70%	3059 42%	2 10%	1316 18%	16 80%	4260 58%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





2.7 Number of Participants on Protease Inhibitor by INGREDIENT

	fosamprenavir		atazanavir		darunavir		lopinavir		ritonavir		saquinavir		tipranavir	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2021	0 0%	1 0%	0 0%	655 32%	5 100%	1297 64%	0 0%	71 4%	0 0%	1 0%	0 0%	6 0%	0 0%	1 0%
FEB-2021	0 0%	1 0%	0 0%	643 33%	5 100%	1262 64%	0 0%	71 4%	0 0%	1 0%	0 0%	5 0%	0 0%	1 0%
MAR-2021	0 0%	1 0%	1 25%	621 32%	3 75%	1261 65%	0 0%	73 4%	0 0%	1 0%	0 0%	5 0%	0 0%	1 0%
APR-2021	0 0%	1 0%	0 0%	595 31%	4 100%	1230 65%	0 0%	72 4%	0 0%	1 0%	0 0%	2 0%	0 0%	1 0%
MAY-2021	0 0%	1 0%	0 0%	589 31%	4 100%	1239 65%	0 0%	69 4%	0 0%	1 0%	0 0%	1 0%	0 0%	1 0%
JUN-2021	0 0%	1 0%	0 0%	573 31%	4 80%	1221 66%	1 20%	69 4%	0 0%	1 0%	0 0%	1 0%	0 0%	1 0%
JUL-2021	0 0%	1 0%	0 0%	560 30%	6 100%	1216 66%	0 0%	68 4%	0 0%	1 0%	0 0%	0 0%	0 0%	1 0%
AUG-2021	0 0%	0 0%	0 0%	547 30%	2 100%	1205 66%	0 0%	66 4%	0 0%	2 0%	0 0%	0 0%	0 0%	1 0%
SEP-2021	0 0%	1 0%	0 0%	536 30%	2 100%	1184 66%	0 0%	61 3%	0 0%	2 0%	0 0%	0 0%	0 0%	1 0%
OCT-2021	0 0%	1 0%	0 0%	515 29%	3 100%	1183 67%	0 0%	59 3%	0 0%	1 0%	0 0%	0 0%	0 0%	1 0%
NOV-2021	0 0%	1 0%	0 0%	508 29%	3 75%	1171 68%	1 25%	58 3%	0 0%	1 0%	0 0%	0 0%	0 0%	1 0%
DEC-2021	0 0%	1 0%	0 0%	492 29%	2 100%	1152 68%	0 0%	58 3%	0 0%	1 0%	0 0%	0 0%	0 0%	1 0%
JAN-2022	0 0%	1 0%	0 0%	476 29%	0 0%	1132 68%	0 0%	60 4%	0 0%	1 0%	0 0%	0 0%	0 0%	1 0%
FEB-2022	0 0%	1 0%	1 33%	448 28%	1 33%	1110 69%	1 33%	60 4%	0 0%	1 0%	0 0%	0 0%	0 0%	1 0%
MAR-2022	0 0%	1 0%	0 0%	431 27%	2 100%	1113 69%	0 0%	57 4%	0 0%	1 0%	0 0%	0 0%	0 0%	1 0%
APR-2022	0 0%	1 0%	0 0%	424 27%	0 0%	1088 69%	0 0%	56 4%	0 0%	1 0%	0 0%	0 0%	0 0%	1 0%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Ritonavir - greater than 400 mg total daily dose





2.8 Number of Participants on Non-Nucleosides by INGREDIENT

	doravirine		efavirenz		etravirine		nevirapine		rilpivirine	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2021	0 0%	11 1%	1 100%	426 34%	0 0%	164 13%	0 0%	379 30%	0 0%	272 22%
FEB-2021	0 0%	15 1%	0 0%	418 34%	0 0%	161 13%	0 0%	365 30%	0 0%	267 22%
MAR-2021	0 0%	21 2%	2 100%	419 34%	0 0%	162 13%	0 0%	365 30%	0 0%	266 22%
APR-2021	0 0%	20 2%	1 50%	409 34%	0 0%	155 13%	1 50%	359 30%	0 0%	260 22%
MAY-2021	1 20%	30 3%	3 60%	397 33%	0 0%	154 13%	0 0%	353 30%	1 20%	259 22%
JUN-2021	0 0%	41 4%	2 100%	379 32%	0 0%	155 13%	0 0%	345 30%	0 0%	251 22%
JUL-2021	0 0%	45 4%	1 100%	371 32%	0 0%	153 13%	0 0%	339 29%	0 0%	243 21%
AUG-2021	0 0%	56 5%	1 100%	366 32%	0 0%	150 13%	0 0%	337 29%	0 0%	241 21%
SEP-2021	0 0%	67 6%	3 75%	357 31%	0 0%	146 13%	0 0%	332 29%	1 25%	242 21%
OCT-2021	1 14%	81 7%	1 14%	350 31%	1 14%	142 12%	1 14%	326 29%	3 43%	244 21%
NOV-2021	0 0%	92 8%	1 33%	346 30%	0 0%	142 13%	0 0%	318 28%	2 67%	244 21%
DEC-2021	0 0%	98 9%	3 75%	340 30%	0 0%	134 12%	0 0%	316 28%	1 25%	243 22%
JAN-2022	0 0%	103 9%	0 0%	328 30%	0 0%	130 12%	0 0%	317 29%	0 0%	235 21%
FEB-2022	0 0%	106 10%	0 0%	317 29%	0 0%	127 12%	0 0%	306 28%	1 100%	228 21%
MAR-2022	0 0%	113 11%	1 100%	303 28%	0 0%	132 12%	0 0%	301 28%	0 0%	223 21%
APR-2022	1 50%	124 12%	1 50%	302 28%	0 0%	130 12%	0 0%	297 28%	0 0%	224 21%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Doravirine not currently available on BC-CfE Formulary





2.9 Number of Participants on Entry/Integrase Inhibitors by INGREDIENT

	bictegravir		dolutegravir		elvitegravir		maraviroc		raltegravir	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2021	12 80%	1697 34%	3 20%	2461 49%	0 0%	442 9%	0 0%	27 1%	0 0%	469 9%
FEB-2021	14 64%	1774 35%	5 23%	2476 49%	3 14%	420 8%	0 0%	24 0%	0 0%	457 9%
MAR-2021	23 72%	1839 35%	9 28%	2491 48%	0 0%	418 8%	0 0%	24 0%	0 0%	454 9%
APR-2021	15 75%	1901 36%	4 20%	2504 48%	1 5%	412 8%	0 0%	22 0%	0 0%	438 8%
MAY-2021	15 65%	1979 37%	7 30%	2509 47%	0 0%	397 7%	0 0%	22 0%	1 4%	439 8%
JUN-2021	16 76%	2056 38%	4 19%	2498 47%	1 5%	387 7%	0 0%	23 0%	0 0%	440 8%
JUL-2021	13 81%	2111 39%	3 19%	2498 46%	0 0%	382 7%	0 0%	23 0%	0 0%	432 8%
AUG-2021	15 71%	2150 40%	5 24%	2488 46%	1 5%	374 7%	0 0%	23 0%	0 0%	424 8%
SEP-2021	18 72%	2192 40%	5 20%	2470 46%	2 8%	366 7%	0 0%	23 0%	0 0%	411 8%
OCT-2021	11 73%	2234 41%	3 20%	2469 45%	1 7%	363 7%	0 0%	24 0%	0 0%	398 7%
NOV-2021	17 77%	2303 42%	4 18%	2459 45%	1 5%	348 6%	0 0%	24 0%	0 0%	392 7%
DEC-2021	8 57%	2348 42%	5 36%	2463 45%	1 7%	349 6%	0 0%	24 0%	0 0%	380 7%
JAN-2022	11 73%	2421 43%	2 13%	2469 44%	1 7%	347 6%	0 0%	24 0%	1 7%	374 7%
FEB-2022	15 71%	2445 44%	6 29%	2438 44%	0 0%	332 6%	0 0%	21 0%	0 0%	370 7%
MAR-2022	24 86%	2540 45%	3 11%	2461 43%	1 4%	326 6%	0 0%	21 0%	0 0%	371 7%
APR-2022	14 74%	2581 45%	5 26%	2440 43%	0 0%	314 6%	0 0%	20 0%	0 0%	366 6%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Category

MON-YYYY	Boosted PI + 2 N(t)RTIs		NNRTI + 2 N(t)RTIs		INSTI + 2 N(t)RTIs		2 drugs from 2 classes		IV 3 drugs from IV 3 classes		Other	
	n	%	n	%	n	%	n	%	n	%	n	%
JAN-2021	1273	17.24	912	12.35	4191	56.76	202	2.74	693	9.39	113	1.53
FEB-2021	1232	16.70	894	12.12	4226	57.29	223	3.02	689	9.34	113	1.53
MAR-2021	1209	16.27	890	11.98	4274	57.51	246	3.31	707	9.51	106	1.43
APR-2021	1166	15.72	868	11.70	4319	58.23	273	3.68	690	9.30	101	1.36
MAY-2021	1146	15.38	858	11.51	4348	58.35	296	3.97	704	9.45	100	1.34
JUN-2021	1125	15.09	834	11.19	4370	58.61	324	4.35	705	9.46	98	1.31
JUL-2021	1104	14.80	820	10.99	4383	58.75	352	4.72	702	9.41	99	1.33
AUG-2021	1090	14.60	817	10.94	4384	58.73	377	5.05	700	9.38	97	1.30
SEP-2021	1070	14.40	812	10.93	4370	58.80	394	5.30	694	9.34	92	1.24
OCT-2021	1053	14.17	809	10.89	4387	59.03	406	5.46	685	9.22	92	1.24
NOV-2021	1038	13.94	804	10.80	4396	59.04	435	5.84	682	9.16	91	1.22
DEC-2021	1020	13.67	790	10.59	4416	59.18	464	6.22	682	9.14	90	1.21
JAN-2022	985	13.19	773	10.35	4452	59.63	496	6.64	673	9.01	87	1.17
FEB-2022	958	12.96	750	10.15	4413	59.71	522	7.06	668	9.04	80	1.08
MAR-2022	934	12.51	737	9.87	4488	60.11	548	7.34	675	9.04	84	1.13
APR-2022	910	12.24	725	9.75	4485	60.31	565	7.60	671	9.02	80	1.08

Definitions:

n is number of participants on the specified regimen class in the specified month

% is ratio of n and total number of participants on ART in the specified month

Regimen categories may contain a small number of participants with undetermined regimen, due to medication change(s) within the month



2.11 Baseline CD4 for Antiretroviral First Starts

MON-YYYY	# of First Starts	# of Pts with CD4 < 100	# of Pts with CD4: 100-199	# of Pts with CD4: 200-349	# of Pts with CD4: 350-500	# of Pts with CD4 > 500	Median CD4
JAN-2021	9	1	3	0	1	2	170
FEB-2021	13	0	2	3	4	4	360
MAR-2021	24	4	5	3	5	5	280
APR-2021	9	2	1	1	1	4	370
MAY-2021	14	1	1	3	2	4	480
JUN-2021	15	4	1	3	2	4	289
JUL-2021	12	1	2	0	2	4	480
AUG-2021	12	1	1	4	2	2	300
SEP-2021	9	0	1	2	2	3	400
OCT-2021	6	1	0	1	0	2	490
NOV-2021	15	3	3	2	2	3	210
DEC-2021	6	1	1	1	3	0	350
JAN-2022	7	1	0	1	1	3	490
FEB-2022	9	0	1	0	1	5	530
MAR-2022	9	4	1	1	1	2	150
APR-2022	1	0	0	0	0	1	820

Definitions:

First Starts defined as starting ARV treatment in the specified month for the first time (ARV naive)

Baseline CD4 is defined as most recent CD4 test before ARV start

2.12 DTP Participants with PVL Measurement within previous five years, and never on ART

MON-YYYY	# of Participants with PVL test	# of Participants with PVL test, and never on ART
JAN-2021	12391	3841
FEB-2021	12384	3836
MAR-2021	12383	3826
APR-2021	12372	3813
MAY-2021	12367	3801
JUN-2021	12368	3795
JUL-2021	12389	3814
AUG-2021	12383	3820
SEP-2021	12352	3788
OCT-2021	12339	3780
NOV-2021	12342	3771
DEC-2021	12323	3766
JAN-2022	12309	3765
FEB-2022	12333	3780
MAR-2022	12362	3795
APR-2022	12393	3820

Definitions:


Patients with PVL test are defined as having at least one PVL test within previous five years, and not reported deceased/moved

Never on ART are subset of patients with PVL test, and not being treated with ARVs on or before specified month




3.1 Distribution of HIV/AIDS Drug Treatment Program Active Participants N = 7436
Apr-2022

BY HEALTH SERVICES DELIVERY AREA




BY HEALTH AUTHORITY






3.2 Distribution of HIV/AIDS Drug Treatment Program Active Participant
Apr-2022

INTERIOR HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA




KELOWNA BY POSTAL CODE






3.3 Distribution of HIV/AIDS Drug Treatment Program Active Participant
Apr-2022

FRASER HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA




SURREY BY POSTAL CODE






3.4 Distribution of HIV/AIDS Drug Treatment Program Active Participant
Apr-2022

VANCOUVER COASTAL HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA




VANCOUVER BY POSTAL CODE






3.5 Distribution of HIV/AIDS Drug Treatment Program Active Participant
Apr-2022

VANCOUVER ISLAND HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA




VICTORIA BY POSTAL CODE






3.6 Distribution of HIV/AIDS Drug Treatment Program Active Participant
Apr-2022

NORTHERN HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



PRINCE GEORGE BY POSTAL CODE



4.1 Distribution of Participants in BC-CfE Registries by Age and Sex at Birth INTERIOR Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
EAST KOOTENAY	20-34	5	5	*
	35-49	13	13	*
	50+	25	41	*
	Total HSDA:	43	59	26
KOOTENAY BOUNDARY	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
Total HSDA:	74	101	57	
OKANAGAN	0-19	*	*	0
	20-34	*	*	25
	35-49	*	*	73
	50+	*	*	211
Total HSDA:	410	557	309	
THOMPSON/CARIBOO/ SHUSWAP	20-34	22	22	13
	35-49	66	71	45
	50+	120	193	90
	Total HSDA:	208	286	148
Total HA:		735	1003	540

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
Total HA:		735	1003	540

Sex at Birth	Alive	Ever treated with ARVs	Currently treated with ARVs
Female	151	206	111
Male	584	797	429

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	540	56	635	35

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)

4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration INTERIOR Health Authority

HSDA	Treatment Duration	Alive	Currently treated with ARVs
EAST KOOTENAY	10 years or more	21	11
	5 years or more	12	6
	<5 years	10	9
	Total HSDA:	43	26
KOOTENAY BOUNDARY	10 years or more	47	33
	5 years or more	14	11
	<5 years	13	13
	Total HSDA:	74	57
OKANAGAN	10 years or more	268	198
	5 years or more	84	65
	<5 years	58	46
	Total HSDA:	410	309
THOMPSON/CARIBOO/ SHUSWAP	10 years or more	131	95
	5 years or more	46	30
	<5 years	31	23
	Total HSDA:	208	148
Total HA:		735	540

Treatment Duration	Alive	Currently treated with ARVs
10 years or more	467	337
5 years or more	156	112
<5 years	112	91
Total HA:	735	540

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation



4.3 Distribution of ARV Prescribers in BC-CfE Registries INTERIOR Health Authority

HSDA of Prescriber Residency	# of Prescribers ever prescribed ARVs	# of Patients ever treated by Prescribers	# of Prescribers currently prescribing ARVs	# of Patients currently treated by Prescribers
EAST KOOTENAY	51	70	13	25
KOOTENAY BOUNDARY	77	135	25	53
OKANAGAN	234	991	54	298
THOMPSON/CARIBOO/SHUSWAP	146	543	35	131
Total:	508	1739	127	507

HSDA of Patient Residency	# of Patients seeking Prescriber's care out of HA
EAST KOOTENAY	*
KOOTENAY BOUNDARY	*
OKANAGAN	*
THOMPSON/CARIBOO/SHUSWAP	*
Total:	108

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Prescriber out of HA is defined as patients residing in specified HSDA, but their follow-up prescriber(s) reside in another HA



4.4 Distribution of Participants in BC-CfE Registries by Age and Sex at Birth FRASER Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
FRASER EAST	0-19	6	6	6
	20-34	34	36	27
	35-49	96	101	65
	50+	250	346	188
	Total HSDA:	386	489	286
FRASER NORTH	20-34	118	118	80
	35-49	353	379	263
	50+	636	1000	482
	Total HSDA:	1107	1497	825
FRASER SOUTH	0-19	5	5	5
	20-34	105	107	76
	35-49	299	332	235
	50+	605	906	487
	Total HSDA:	1014	1350	803
Total HA:		2507	3336	1914

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	11	11	11
	20-34	257	261	183
	35-49	748	812	563
	50+	1491	2252	1157
Total HA:		2507	3336	1914

Sex at Birth	Alive	Ever treated with ARVs	Currently treated with ARVs
Female	609	778	448
Male	1898	2558	1466

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	1914	53	657	35

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)

4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration FRASER Health Authority

HSDA	Treatment Duration	Alive	Currently treated with ARVs
FRASER EAST	10 years or more	245	184
	5 years or more	77	53
	<5 years	64	49
	Total HSDA:	386	286
FRASER NORTH	10 years or more	681	481
	5 years or more	243	195
	<5 years	183	149
	Total HSDA:	1107	825
FRASER SOUTH	10 years or more	624	489
	5 years or more	232	175
	<5 years	158	139
	Total HSDA:	1014	803
Total HA:		2507	1914

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	1550	1154
	5 years or more	552	423
	<5 years	405	337
Total HA:		2507	1914

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation



4.6 Distribution of ARV Prescribers in BC-CfE Registries FRASER Health Authority

HSDA of Prescriber Residency	# of Prescribers ever prescribed ARVs	# of Patients ever treated by Prescribers	# of Prescribers currently prescribing ARVs	# of Patients currently treated by Prescribers
FRASER EAST	142	518	28	53
FRASER NORTH	257	1594	45	225
FRASER SOUTH	226	1742	51	485
Total:	625	3854	124	763

HSDA of Patient Residency	# of Patients seeking Prescriber's care out of HA
FRASER EAST	185
FRASER NORTH	684
FRASER SOUTH	458
Total:	1327

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Prescriber out of HA is defined as patients residing in specified HSDA, but their follow-up prescriber(s) reside in another HA



4.7 Distribution of Participants in BC-CfE Registries by Age and Sex at Birth VANCOUVER COASTAL Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
NORTH SHORE/ COAST GARIBALDI	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		357	516
RICHMOND	20-34	31	32	16
	35-49	50	52	41
	50+	114	166	94
	Total HSDA:	195	250	151
VANCOUVER	0-19	11	11	9
	20-34	438	455	300
	35-49	1255	1407	887
	50+	2947	5182	2118
	Total HSDA:	4651	7055	3314
Total HA:		5203	7821	3748

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	12	12	10
	20-34	498	516	337
	35-49	1389	1551	989
	50+	3304	5742	2412
Total HA:		5203	7821	3748

Sex at Birth	Alive	Ever treated with ARVs	Currently treated with ARVs
Female	603	955	435
Male	4598	6864	3313
Unknown	2	2	0

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	3748	55	650	35

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)

4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration VANCOUVER COASTAL Health Authority

HSDA	Treatment Duration	Alive	Currently treated with ARVs
NORTH SHORE/ COAST GARIBALDI	10 years or more	224	174
	5 years or more	75	63
	<5 years	58	46
	Total HSDA:	357	283
RICHMOND	10 years or more	118	89
	5 years or more	31	23
	<5 years	46	39
	Total HSDA:	195	151
VANCOUVER	10 years or more	3157	2161
	5 years or more	888	660
	<5 years	606	493
	Total HSDA:	4651	3314
Total HA:		5203	3748

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	3499	2424
	5 years or more	994	746
	<5 years	710	578
Total HA:		5203	3748

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation

4.9 Distribution of ARV Prescribers in BC-CfE Registries VANCOUVER COASTAL Health Authority

HSDA of Prescriber Residency	# of Prescribers ever prescribed ARVs	# of Patients ever treated by Prescribers	# of Prescribers currently prescribing ARVs	# of Patients currently treated by Prescribers
NORTH SHORE/COAST GARIBALDI	182	411	54	80
RICHMOND	44	300	8	91
VANCOUVER	663	11310	211	5339
Total:	889	12021	273	5510

HSDA of Patient Residency	# of Patients seeking Prescriber's care out of HA
NORTH SHORE/COAST GARIBALDI	*
RICHMOND	*
VANCOUVER	*
Total:	86

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Prescriber out of HA is defined as patients residing in specified HSDA, but their follow-up prescriber(s) reside in another HA

4.10 Distribution of Participants in BC-CfE Registries by Age and Sex at Birth VANCOUVER ISLAND Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
CENTRAL VANCOUVER ISLAND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		346	504
NORTH VANCOUVER ISLAND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		121	169
SOUTH VANCOUVER ISLAND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		777	1116
Total HA:		1244	1789	969

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	6	6	5
	20-34	113	124	74
	35-49	281	323	220
	50+	844	1336	670
Total HA:		1244	1789	969

Sex at Birth	Alive	Ever treated with ARVs	Currently treated with ARVs
Female	214	312	164
Male	1030	1477	805

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	969	56	590	35

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)

4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration VANCOUVER ISLAND Health Authority

HSDA	Treatment Duration	Alive	Currently treated with ARVs
CENTRAL VANCOUVER ISLAND	10 years or more	210	171
	5 years or more	79	60
	<5 years	57	45
	Total HSDA:	346	276
NORTH VANCOUVER ISLAND	10 years or more	83	71
	5 years or more	26	16
	<5 years	12	11
	Total HSDA:	121	98
SOUTH VANCOUVER ISLAND	10 years or more	474	342
	5 years or more	158	130
	<5 years	145	123
	Total HSDA:	777	595
Total HA:		1244	969

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	767	584
	5 years or more	263	206
	<5 years	214	179
Total HA:		1244	969

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation



**4.12 Distribution of ARV Prescribers in BC-CfE Registries
VANCOUVER ISLAND Health Authority**

HSDA of Prescriber Residency	# of Prescribers ever prescribed ARVs	# of Patients ever treated by Prescribers	# of Prescribers currently prescribing ARVs	# of Patients currently treated by Prescribers
CENTRAL VANCOUVER ISLAND	202	911	75	196
NORTH VANCOUVER ISLAND	154	275	40	68
SOUTH VANCOUVER ISLAND	219	1890	38	583
Total:	575	3076	153	847

HSDA of Patient Residency	# of Patients seeking Prescriber's care out of HA
CENTRAL VANCOUVER ISLAND	63
NORTH VANCOUVER ISLAND	42
SOUTH VANCOUVER ISLAND	129
Total:	234

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Prescriber out of HA is defined as patients residing in specified HSDA, but their follow-up prescriber(s) reside in another HA



4.13 Distribution of Participants in BC-CfE Registries by Age and Sex at Birth NORTHERN Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
NORTH EAST	20-34	5	5	*
	35-49	18	21	*
	50+	24	32	*
	Total HSDA:	47	58	25
NORTH WEST	20-34	*	6	0
	35-49	*	38	19
	50+	*	75	36
	Total HSDA:	72	119	55
NORTHERN INTERIOR	0-19	6	6	*
	20-34	22	24	*
	35-49	54	70	*
	50+	109	186	*
	Total HSDA:	191	286	142
Total HA:		310	463	222

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	6	6	*
	20-34	31	35	*
	35-49	96	129	*
	50+	177	293	*
Total HA:		310	463	222

Sex at Birth	Alive	Ever treated with ARVs	Currently treated with ARVs
Female	114	173	79
Male	196	290	143

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	222	53	560	35

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)

4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration NORTHERN Health Authority

HSDA	Treatment Duration	Alive	Currently treated with ARVs
NORTH EAST	10 years or more	29	*
	5 years or more	6	*
	<5 years	12	*
	Total HSDA:	47	25
NORTH WEST	10 years or more	48	35
	5 years or more	14	12
	<5 years	10	8
	Total HSDA:	72	55
NORTHERN INTERIOR	10 years or more	98	76
	5 years or more	56	39
	<5 years	37	27
	Total HSDA:	191	142
Total HA:		310	222

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	175	126
	5 years or more	76	53
	<5 years	59	43
Total HA:		310	222

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation



**4.15 Distribution of ARV Prescribers in BC-CfE Registries
NORTHERN Health Authority**

HSDA of Prescriber Residency	# of Prescribers ever prescribed ARVs	# of Patients ever treated by Prescribers	# of Prescribers currently prescribing ARVs	# of Patients currently treated by Prescribers
NORTH EAST	38	61	3	*
NORTH WEST	84	169	19	*
NORTHERN INTERIOR	118	489	19	*
Total:	240	719	41	228

HSDA of Patient Residency	# of Patients seeking Prescriber's care out of HA
NORTH EAST	*
NORTH WEST	*
NORTHERN INTERIOR	*
Total:	37

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Prescriber out of HA is defined as patients residing in specified HSDA, but their follow-up prescriber(s) reside in another HA



4.16 Distribution of Indigenous Participants in BC-CfE Registries by Health Service Delivery Area and Sex at Birth

HA	HSDA	Alive	Ever treated with ARVs	Currently treated with ARVs
INTERIOR	EAST KOOTENAY	5	11	*
	KOOTENAY BOUNDARY	6	9	*
	OKANAGAN	29	47	*
	THOMPSON/CARIBOO/SHUSWAP	26	50	*
	Total HA:	66	117	46
FRASER	FRASER EAST	33	46	23
	FRASER NORTH	57	96	46
	FRASER SOUTH	83	118	57
	Total HA:	173	260	126
VANCOUVER COASTAL	NORTH SHORE/COAST GARIBALDI	30	53	26
	RICHMOND	6	11	5
	VANCOUVER	463	895	372
	Total HA:	499	959	403
VANCOUVER ISLAND	CENTRAL VANCOUVER ISLAND	45	79	37
	NORTH VANCOUVER ISLAND	13	25	10
	SOUTH VANCOUVER ISLAND	46	93	39
	Total HA:	104	197	86
NORTHERN	NORTH EAST	10	14	6
	NORTH WEST	32	67	26
	NORTHERN INTERIOR	66	112	55
	Total HA:	108	193	87
Total:		950	1726	748

Sex at Birth	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	601	1107	476
Female	349	619	272

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total:	748	53	500	35

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)



5.1 Drug Names and Definitions

Abacavir: a NUCLEOSIDE ANALOG from ViiV Healthcare.

Active: persons in the HIV/AIDS Drug Treatment program that are prescribed one or more drugs in this current month

Antiretroviral: a substance that stops or suppresses the activity of a retrovirus, such as HIV. NUCLEOSIDE ANALOGS and PROTEASE INHIBITORS are examples of antiretroviral drugs.

Atazanavir (Reyataz): a PROTEASE INHIBITOR from Bristol-Myers Squibb.

Atovaquone (Mepron): a medication used to treat pneumocystis carinii pneumonia and, in some cases, toxoplasmosis.

Atripla: the Bristol-Myers Squibb and Gilead trade name for a tablet containing EFAVIRENZ, TENOFOVIR DF and EMTRICITABINE.

Azithromycin (Zithromax): an antibiotic used for the prevention of mycobacterium avium complex (MAC) in people with advanced HIV infection.

Bictegravir: an INTEGRASE INHIBITOR from Gilead Sciences.

Boosted PI: a PI and a small (400 mg or less, total daily dose) additional dose or RITONAVIR. The addition of RITONAVIR inhibits metabolism of other PIs and improves their exposure. This may allow for decreased dosing frequency or pill burden and may improve adherence and antiretroviral activity.

CD4 Cell Count: the most commonly used marker for assessing the state of the immune system. As CD4 cell count declines, the risk of developing opportunistic infections increases. Normal CD4 cell counts are greater than 800 per cubic millimeter of blood.

Chemokine Receptor Inhibitor: a type of ENTRY INHIBITOR designed to prevent HIV entry by blocking the binding site of co-receptors, such as CCR5 or CXCR4.

Clarithromycin (Biaxin): an antibiotic used for the treatment of mycobacterium avium complex (MAC). It is also used for preventing MAC in those with advanced HIV infection.

Cobicistat: a pharmacokinetic enhancer (“booster”) given with other antiretrovirals to improve drug exposure. Cobicistat has no anti-HIV activity. It is currently available as a component of STRIBILD, GENVOYA and PREZCOBIX.

Combination Therapy: initial combination therapy for HIV contains at least three ANTIRETROVIRALS.

Complera: the Gilead trade name for a tablet containing EMTRICITABINE, RILPIVIRINE and TENOFOVIR DF.

Darunavir (Prezista): a PROTEASE INHIBITOR from Janssen that has activity against HIV in treatment-experienced patients.

Deceased: persons enrolled in the HIV/AIDS Drug Treatment program that died in this time period.

Descovy: the Gilead trade name for a tablet containing EMTRICITABINE and TENOFOVIR AF.

Didanosine (Videx): a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.

Dolutegravir (Tivicay): an INTEGRASE INHIBITOR from ViiV Healthcare.





Monthly Report

Doravirine: a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Merck.

Efavirenz (Sustiva, Auro efavirenz): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Bristol-Myers Squibb.

Elvitegravir: an INTEGRASE INHIBITOR from Gilead Sciences. It is currently available as a component of STRIBILD.

Emtricitabine: a NUCLEOSIDE ANALOG from Gilead Sciences. It is currently available as a component of TRUVADA and other combinations.

Enfuvirtide (Fuzeon): a FUSION INHIBITOR from Hoffman-La Roche that targets the gp41 protein on the surface of HIV. It is administered as a subcutaneous injection.

Entry Inhibitor: a drug that inhibits the entry of HIV into cells. Entry inhibitors include FUSION INHIBITORS, CHEMOKINE RECEPTOR INHIBITORS, and attachment inhibitors.

Etravirine (Intence): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR from Janssen that has activity against HIV in treatment-experienced patients.

First started program: a person prescribed their first regimen ever in the HIV/AIDS drug treatment program.

Fosamprenavir (Telzir): a PROTEASE INHIBITOR from ViiV Healthcare. Fosamprenavir is a PRODRUG of AMPRENAVIR.

Fusion Inhibitor: a type of ENTRY INHIBITOR designed to prevent HIV from fusing with and thereby infecting CD4 cells.

Genvoya: the Gilead trade name for a tablet containing ELVITEGRAVIR, COBICSTAT, EMTRICITABINE and TENOFOVIR AF.

Health Authority: refers to the five (Interior, Fraser, Northern, Vancouver Coastal, Vancouver Island) health authorities created by the BC Ministry of Health.

Inactive: persons no longer dispensed drugs through the HIV/AIDS Drug Treatment program this current month.

Integrase Inhibitor: a drug that blocks integrase, a protein that HIV needs to enter cells and produce copies of itself, from working.

Kivexa: the ViiV Healthcare's trade name for a tablet containing both ABACAVIR and LAMIVUDINE.

Lamivudine: a NUCLEOSIDE ANALOG from ViiV Healthcare with activity against HIV and hepatitis B.

Lopinavir (Kaletra): a PROTEASE INHIBITOR from Abbott Laboratories. Kaletra is a combination of lopinavir and a low dose of RITONAVIR, a drug that improves blood levels of lopinavir.

Maraviroc (Celsentri): a CHEMOKINE RECEPTOR INHIBITOR from ViiV Healthcare that inhibits HIV entry by blocking the binding site of the CCR5 co-receptor.

Median (MED) age: median age of participants in the HIV/AIDS Drug Treatment program in that time period.

MDRT: see MULTIPLE DRUG RESCUE THERAPY

Moved out of BC: a person in the HIV/AIDS Drug Treatment program that is no longer in the program, because they moved out of BC in this time period.





Monthly Report

Multiple Drug Rescue Therapy (MDRT or Mega-HAART): the use of five or more antiretrovirals to treat HIV, typically some or all of which have been used previously by the individual.

Nelfinavir (Viracept): a PROTEASE INHIBITOR from ViiV Healthcare.

Net change: the net increase or decrease in persons enrolled in the HIV/AIDS Drug Treatment Program from the previous time period.

Nevirapine (Viramune): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Boehringer Ingelheim.

NNRTI: see NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR.

NNRTI / no PI: a combination therapy regimen of four or fewer antiretroviral drugs, including an NNRTI, but no PIs.

Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI): a member of a class of compounds, including DELAVIRDINE, NEVIRAPINE, EFAVIRENZ and ETRAVIRINE that acts to directly combine with and block the action of HIV's reverse transcriptase enzyme.

N(t)RTI: a category of drug encompassing both NUCLEOSIDE ANALOG and NUCLEOTIDE ANALOG

Nucleoside Analog (Nucleoside Analog Reverse Transcriptase Inhibitor, NRTI): a type of ANTIVIRAL drug whose structure constitutes a defective version of a natural nucleoside. Nucleoside analogs may take the place of the natural nucleosides, blocking the completion of a viral DNA chain during infection of a new cell by HIV. The HIV enzyme reverse transcriptase is more likely to incorporate nucleoside analogs into the DNA it is constructing than is the DNA polymerase that cells normally use for DNA construction.

Nucleotide Analog: ANTIVIRAL compounds that function exactly like NUCLEOSIDE ANALOGS but are pre-activated through the addition of a phosphate group during their synthesis. This phosphorylation is supposed to enhance the drug levels and activity achieved within cells.

Odefsey: the Gilead trade name for a tablet containing RILPIVIRINE, EMTRICITABINE and TENOFOVIR AF.

One or more PI: a combination therapy regimen of four or fewer antiretroviral drugs, including one unboosted PI or 2 or more PIs with or without a small (400 mg or less, total daily dose) additional dose of RITONAVIR.

Other: an antiretroviral regimen in the HIV/AIDS Drug Treatment program other than NNRTI/no PI, boosted PI, 1 or more PIs or MDRT-based regimens (eg. Triple Nucleoside regimens).

Pentamidine: an antiprotozoal drug used in aerosol form as a preventative against pneumocystis carinii pneumonia (PCP).

PI: see PROTEASE INHIBITOR.

Prezcobix: the Janssen trade name for a tablet containing DARUNAVIR and COBICISTAT.

Prodrug: a compound that is converted within the body into the active form that has medical effects.

Protease Inhibitor: a drug that binds to and blocks HIV protease from working, thus preventing the production of new functional viral particles.

Raltegravir (Isentress): an INTEGRASE INHIBITOR from Merck.

Restarted/ changed therapy (Tx): a person in the HIV/AIDS Drug Treatment program that was either CURRENTLY OFF THERAPY and now has been prescribed a new regimen or a person who has changed regimens.





Monthly Report

Rifabutin (Mycobutin): an oral drug used to prevent mycobacterium avium complex (MAC) in people with advanced HIV infection. Rifabutin is also used in combination with other drugs for the treatment of active MAC infections.

Rilpivirine (Edurant): a NON-NUCELOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Janssen.

Ritonavir (Norvir): a PROTEASE INHIBITOR from Abbott. Ritonavir is commonly used to inhibit the liver enzyme metabolism of other protease inhibitors and improve their blood exposure (“booster”).

Saquinavir (Invirase): a PROTEASE INHIBITOR from Hoffman-La Roche.

Stavudine (Zerit): a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.

Stopped all therapies (Tx): a person in the HIV/AIDS Drug Treatment program that stopped all therapies in this time period and is now CURRENTLY OFF THERAPY.

Stribild: the Gilead trade name for a tablet containing ELVITEGRAVIR, COBICISTAT, EMTRICITABINE and TENOFOVIR DF.

Tenofovir alafenamide (Tenofovir AF, TAF): a NUCLEOTIDE ANALOG from Gilead Sciences with activity against HIV. It is currently available as a component of DESCOVY and GENVOYA.

Tenofovir disoproxil fumarate (Viread, Tenofovir DF, TDF): a NUCLEOTIDE ANALOG from Gilead Sciences with activity against HIV and hepatitis B.

Tipranavir (Aptivus): a PROTEASE INHIBITOR from Boehringer Ingelheim that has activity against HIV in treatment-experienced patients.

Triple Therapy: the use of three drugs, most often a PROTEASE INHIBITOR or NON-NUCLEOSIDE ANALOG with two NUCLEOSIDE ANALOGS, in the treatment of HIV.

Triumeq: the ViiV Healthcare’s trade name for a tablet containing DOLUTEGRAVIR, ABACAVIR and LAMIVUDINE.

Trizivir: the ViiV Healthcare’s trade name for a tablet containing ABACAVIR, ZIDOVUDINE and LAMIVUDINE.

Truvada: the Gilead trade name for a tablet containing TENOFOVIR DF and EMTRICITABINE.

Valganciclovir: an antiviral drug used to treat cytomegalovirus (CMV) retinitis.

Viral Load: the amount of HIV RNA per unit of blood plasma. An indicator of virus concentration and reproduction rate. HIV viral load is employed as a measure of the success of antiretroviral therapy.

Zidovudine (Retrovir): a NUCLEOSIDE ANALOG from ViiV Healthcare. AZT is also approved for preventing maternal-fetal HIV transmission.

